<div id="readability-page-1"><p>In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Hold rating on Sarepta Therapeutics, with a price target of <span id="expert-recommendation-target">$17.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Clark-Gartner covers the Healthcare sector, focusing on stocks such as AbbVie, Vera Therapeutics, and Insmed. According to TipRanks, Clark-Gartner has an average return of <span>25.6%</span> and a 66.67% success rate on recommended stocks. </p> <p>Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $21.24.</p></div>

SRPT

<p>Evercore ISI's Gavin Clark-Gartner maintains a Hold rating on Sarepta Therapeutics with a $17.00 price target. The analyst, who covers the Healthcare sector, has a 25.6% average return and a 66.67% success rate. Sarepta's analyst consensus is Hold, with a $21.24 price target consensus.</p>

Evercore ISI Remains a Hold on Sarepta Therapeutics (SRPT)